Nexalin appoints Carolyn Shelton as SVP Quality, Regulatory & Clinical Affairs

Nexalin Technology, Inc.

Carolyn Shelton appointed SVP Quality, Regulatory and Clinical Affairs effective Sept 16, 2024.
Base salary of $300,000; annual discretionary bonus of $40,000 based on milestones.
Stock options valued at $60,000 under 2023 Equity Incentive Plan, vesting equally over 3 years from Sept 16, 2025.
Prior roles include VP Regulatory/Quality at Openwater Health, Advanced Sterilization Products, and Medtronic.
Relocation expenses up to $5,000; five weeks paid time off per year.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carolyn Shelton

Senior Vice President Quality, Regulatory and Clinical Affairs

NXL · Nexalin Technology, Inc.

Effective: 2024-09-16
Filed: September 19, 2024, 7:59 PM ET

On September 16, 2024, Nexalin Technology, Inc. (“Nexalin”) appointed Carolyn Shelton as Senior Vice President Quality, Regulatory and Clinical Affairs, effective as of September 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carolyn Shelton was appointed as Senior Vice President Quality, Regulatory and Clinical Affairs at Nexalin Technology, Inc..

Action: appointed
Role: Senior Vice President Quality, Regulatory and Clinical Affairs

Exact text from the filing

On September 16, 2024, Nexalin Technology, Inc. (“Nexalin”) appointed Carolyn Shelton as Senior Vice President Quality, Regulatory and Clinical Affairs, effective as of September 16, 2024.

View on SEC.gov

Nexalin Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-24-006349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.